# THORACIC SURGERY ONCOLOGY GROUP NEWS FALL 2023

A collaboration between AATS and Memorial Sloan Kettering Cancer Center



FROM THE TSOG CHAIR

TSOG continues to push the envelope and remain relevant. In this issue, we will take a look at TSOG's reaching target accrual of one of its first investigatorinitiated trials. This is in part due to the efforts of the TSOG Investigators and Site Coordinators. TSOG has expanded to include 32 sites in total, welcoming new sites University of Minnesota (PI, Ilitch Gutierrez, MD): New York Presbyterian Hospital/ Weill Cornell Medical Center (PI, Nasser Altorki, MD); Mayo Clinic-Jacksonville (PI, Ian Makey, MD); McGill University (PI, Jonathan Spicer, MD); NorthShore University HealthSystem (PI, Seth



Krantz, MD); and University of Chicago (PI, Jessica Donington, MD). In this newsletter, we celebrate the TSOG 102 GGO Study (PI, James Huang, MD). This is the first TSOG study that has reached target accrual. We will also share plans to increase TSOG's social media presence.

### –David R. Jones

#### IN THIS ISSUE

**TSOG 102 GGO Study Reaches Target Accrual** Page 2

**Update on Current TSOG Trials** Page 3

**TSOG Social Media Presence** Page 4



## **TSOG 102 GGO Study Reaches Target Accrual**

#### **TSOG 102**

"Registry trial for the active surveillance for multifocal ground glass opacities (GGOs)," led by Dr. James Huang, from Memorial Sloan Kettering Cancer Center, has reached its target accrual (N=330). Twenty-one TSOG sites across North America accrued patients to this trial. This is the first clinical trial that TSOG has finished, and credit goes to the investigators and their teams who put patients on trial. The most recent site activations were located at the University of Pennsylvania (study PI, Doraid Jarrar, MD), Fox Chase Cancer Center (study PI, Stacy Su, MD), and New York Presbyterian Hospital/ Weill Cornell Medical Center (study PI, Nasser Altorki, MD). Championed by study PI Matthew Rochefort, MD,

Brigham and Women's Hospital is the second highest accruing TSOG site for this trial, with 34 patients on study since its activation in September 2020. Patients on study will still need to be followed up as part of the trial protocol, so our work is not done. Dr. Huang is working on an abstract of the study, which will be available for review by 2024, so please continue following up on data requests in a timely fashion. It is nice to celebrate the first completed clinical trial from AATS-MSK TSOG. It is a milestone for TSOG and the AATS in that it is an achievement that has never been attempted, much less completed, other thoracic by any surgical association or society. To read more about this study's accomplishments, please see this AATS press release.

# **Update on Current TSOG Trials**

#### **TSOG 101**

"Evaluation of perioperative circulating Medicine. After the study's activation tumor DNA analysis as a prognostic in July 2021, Thomas Jefferson biomarker in patients undergoing University is the second highest neoadjuvant therapy for resectable accruing site, with 4 patients on study. non-small cell lung cancer," led by By the end of 2022, the trial closed Dr. Sloan Kettering Cancer Center, is patients on study will be followed for open to accrual at 15 sites, with hopes survival. As of November 2023, the trial of closing in 2023. As of June 2023, has 46 patients on study across all sites.



there are 86 patients on study across The PI feels there is still useful data all sites. Most recently, TSOG 101 from the accrued patients and will opened to accrual at West Virginia look into possibly reframing the study University (study PI, Alper Toker, aims on the basis of the data collected. MD) and Mayo Clinic-Jacksonville (study PI, Ian Makey, MD). Since the **TSOG 105** study's activation in June 2021, the "Comparing the effectiveness" University of Montreal has accrued surgery versus stereotactic body 21 patients and continues to maintain radiation therapy for stage I non-small the title as second highest accruing cell lung cancer (SORT)," a previous site, with PI Moishe Liberman, MD. TSOG proposal, led by Dr. Benjamin


#### **TSOG 103**

multimodality management in risk- University, Memorial Sloan Kettering stratified patients with lung-limited Cancer Center, MD Anderson Cancer metastatic colorectal cancer," led by Center, University of Toronto/ Dr. Mara Antonoff, from MD Anderson University Health Network, and Duke Cancer Center, has continued to expand, University. There will be a total of 8 sites

with an activation at Baylor College of James Isbell, from Memorial at sites due to low accrual. Current



of Kozower, from Washington University, is open to accrual at the following Since Winter 2021, "The role of participating TSOG sites: Washington



participating in this trial, which includes non-TSOG sites Cleveland Clinic, Emory University, and Carle Clinic. This NCI-funded, multicenter, prospective cohort study is designed to compare the effectiveness of surgery versus SBRT on stakeholder-selected outcomes in patients with clinical stage I NSCLC.

As of November 2023, the study has 189 patients on study at all sites. Since the study's activation in July 2022, Washington University leads accrual with 106 patients on study. This is followed by Memorial Sloan Kettering Cancer Center as the second highest accruing site, which has 30 patients on study since activation at the site in November 2022. The trial's Research Team Site Coordinators meet monthly on the first Monday of each month, and study PIs meet quarterly, with their last meeting held in October 2023.

# $\mathbb{X}$

#### Visit TSOG Soon on X, Formerly Known as Twitter

TSOG would like to increase its social media presence. We would like to do this by using X, formerly known as Twitter, as a platform to communicate news and information about TSOG and to encourage public awareness of the aroup and thereby expand membership. Stay tuned @TSOG ClinTrials.



#### You Can NOW Visit the AATS/TSOG Webpages

The TSOG website provides a brief description of TSOG, our trials, participating sites, Executive Board, administrative and staff contacts, and newsletters. Feel free to visit the site today.

https://www.aats.org/about-the-aats/ thoracic-surgical-oncology-group